Skip to Content
Hae Menu

CAR-T cell therapy provides early and deep response in multiple myeloma patients

Initial data from the phase II study CARTITUDE-2 show that patients with refractory multiple myeloma received an early and deep response to treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta cell).

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Asiaan liittyvä sisältö

Azacitidine was generally well tolerated in patients ≥ 75 years of age in QUAZAR AML-001

/ BestPractice Nordic
EHA21AML

mutNPM1 status is a prognostic and an independent predictive marker for improved survival with azacitidine

/ BestPractice Nordic
EHA21AML

The first-in-class antibody talquetamab show a high clinical response rate in patients with relapsed and refractory multiple myeloma

/ BestPractice Nordic
myeloomaEHA21
Back to top